{"description":"All treated population include all participants who received at least 1 dose of study intervention.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":5,"description":"Participants with KRAS G12C-mutant Advanced Solid Tumors were treated with a single dose of BMS-986466 10 mg orally (PO) on Cycle 1 Day 1 and Day 9 and followed by regular administration from Cycle 3 Day 1 till study discontinuation. Participants were also administered with adagrasib 400 mg twice a day (BID) starting on Cycle 1 Day 4.","id":"EG000","otherNumAffected":4,"otherNumAtRisk":5,"seriousNumAffected":1,"seriousNumAtRisk":5,"title":"Part 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":5}],"term":"Constipation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":5}],"term":"Diarrhoea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Epigastric discomfort"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":5}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Proctalgia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Vomiting"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Alanine aminotransferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Amylase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Aspartate aminotransferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Lipase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Decreased appetite"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Dehydration"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Muscle spasms"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Somnolence"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Hypotension"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"27.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5}],"term":"Pyrexia"}],"timeFrame":"All cause mortality, and serious and non-serious adverse events were collected from from first dose until 100 days after last dose (Up to approximately 5 months)."}